#RENE

Totally agree $CDAK are around 18months further advanced in the development of Exosomes (delivery vehicle)

#RENE Mcap= £60m
$CDAK MCap= $591m

3 Companies evaluating RENE's platform

Currently snowed under with demand off other companies for Proof of Concept trials https://twitter.com/Stockonomist/status/1347110428095229952

#RENE

Are exosomes going to play a big role in future cell and gene delivery?

#RENE

One of the brilliant things which Exosomes do is they have the ability to pass through the Blood Brain Barrier delivering signals and regulation into the Brain

This is extremely difficult to do and most drug delivery mechanisms fail to do this

#RENE

David Sinclair
A Professor in Genetics At Harvard Medical School
Who specialises in the Biology of Ageing explains
3min30sec


As we age “Sirtuins” which protect the body loose their ability to Silence (siRNA) Genes which should not be there

#RENE

He believes this is partly why we have Diseases of the Brain

RENE have stayed in their recent Webinar exceptional demand from Top Cell and Gene Therapy players to partner with their Exosome platform, a platform that had already proven it can package siRNA and mRNA

#RENE

The question is over the next 12 months HOW MANY Major Global Cell and Gene Therapy players will RENE develop partnerships with?

#RENE

Exosome Collaboration Deals to date include

MAJOR Pharma
MAJOR Biotech

Including research grants from Innovative UK

Demand for their Exosome platform currently OUTSTRIPPING their functional capacity showing this delivery mechanism to potentially be breakthrough

#RENE

Update from the CEO regarding their Phase 2 trial in Retinitis pigmentosa (RP) an Eye Disease that causes blindness

Only Therapeutic currently on the market addresses 2% of the RP population

ReNeurons therapy shown to treat 100% of the population

#RENE

A little understanding of Retinitis pigmentosa (RP)

#RENE

Not only has RENE stem cell therapy
prevented continued deterioration
of vision it has
significant improved and restored vision on average by 8-10 letters

#RENE

This is exciting as EYLEA
(One of the best selling drugs in the world)
Was approved on a visual acuity improvement of 9 Letters

In a different Eye Condition
(Wet AMD)

#RENE

ReNeuron aren’t stopping there

They have decided to DOUBLE the dose in a further Extension study to try to increase the efficacy even further

AIM: Letter Improvement increase from 8/10 Letters 15+ Letters and it’s virtually near enough certain for approval

#RENE

1st Patient in the increased dose cohort was reviewed by Data Safety Monitoring board

Allowing RENE to proceed to dose a further 2 patients before the next evaluation

This is an encouraging sign that there are no Serious Adverse Events relating to the increased dose

#RENE

3/9 Patients have now been dosed and shortly we will receive a thorough Safety update of the expanded cohort which I anticipated to be good

This trial is open label (ReNeuron can see the safety and results as they go along)

#RENE

Given the recent enthusiasm by both the CEO and the Principal Investigator validates the thesis that the expansion Cohort will be Safe

Potentially showing further improved GAME CHANGING results for this “innovative” Stem Cell Therapy

#RENE

Validation of the HUGE promise of Exosomes

Highly educated individual with vast knowledge and experiance within Medical Research
Ex Chief Scientific Officer to $81.6Bn Gilead

#RENE

Are Exosomes actually the key driver in treating disease

Understand the bodies deep mechanisms beyond cell therapy...

#RENE

Are Exosome infused miRNA the next generation Cell Therapies?